EP4232103A1 - Matériau bidimensionnel pour le traitement médical d'une zone de plaie - Google Patents

Matériau bidimensionnel pour le traitement médical d'une zone de plaie

Info

Publication number
EP4232103A1
EP4232103A1 EP21835199.7A EP21835199A EP4232103A1 EP 4232103 A1 EP4232103 A1 EP 4232103A1 EP 21835199 A EP21835199 A EP 21835199A EP 4232103 A1 EP4232103 A1 EP 4232103A1
Authority
EP
European Patent Office
Prior art keywords
collagen particles
collagen
flat material
weight
woven fabric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21835199.7A
Other languages
German (de)
English (en)
Inventor
Heinrich Planck
Erhard Müller
Svenja Reimer
Christian PLANCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymedics Innovations GmbH
Original Assignee
Polymedics Innovations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymedics Innovations GmbH filed Critical Polymedics Innovations GmbH
Publication of EP4232103A1 publication Critical patent/EP4232103A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0033—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/009—Materials resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones

Definitions

  • the present invention relates to a sheet material for medical treatment of wound surfaces.
  • resorbable surface materials have become established. B. as a skin replacement material for burns or for the treatment of so-called decollements, ie leather wounds on the skin. Such a flat material is known, for example, from EP 1 181 941 A2 and is marketed by Polymedics GmbH, Germany, under the name Suprathel®.
  • the well-known resorbable surface material offers pain-relieving and anti-infective effects in open wound surface treatment and allows a largely undisturbed formation of granulation tissue with good mechanical properties at the same time.
  • the surface material On bloody or wound surfaces wetted with exudate, however, the surface material only has a slow capacity to adsorb and absorb liquids, which limits the haemostatic effect of the surface material.
  • the flat material has a non-woven fabric made of resorbable polymer filaments, in or on which collagen particles with a particle size of more than 80 ⁇ m are arranged. Due to the swelling capacity of fibrillar, i. H. In collagen that is intact in its secondary or tertiary structure, the binding of water to the cover membrane can be accelerated and the water-binding capacity of the cover membrane per unit area can be increased.
  • structurally intact collagen is understood to mean collagen whose ⁇ and ⁇ bands can be detected in the SDS-PAGE test.
  • collagen particles are anchored in or on the highly porous nonwoven fabric made of resorbable polymer filaments, which itself is water-absorbent, excess blood plasma and/or wound exudate can be removed more quickly and effectively from the wound surface when applied to the wound surface.
  • a particularly rapid bioavailability of the collagen particles of the surface material is made possible.
  • vWF von Willebrand factor
  • fibrillar collagen comes into contact with a wound, it is known that the binding of the von Willebrand factor (vWF) to the fibrillar collagen and to the corresponding receptor of the thrombocyte membrane of thrombocytes and the adhesion of thrombocytes is promoted.
  • the emptying of platelet granules (degranulation) can be increased and thus plasmatic blood coagulation (secondary hemostasis) are triggered or reinforced.
  • planar material With a correspondingly flexibly deformable design of the planar material, it can easily be adapted even to wound areas of the skin that are regularly difficult to cover, for example in the area of joints.
  • the collagen particles preferably have a particle size in the range from 80 ⁇ m to 500 ⁇ m, particularly preferably in the range from 100 ⁇ m to 250 ⁇ m, very particularly preferably in the range from 100 ⁇ m to 150 ⁇ m.
  • the haemostatic effect of the collagen in situ decreases beyond an average particle size of approximately 500 ⁇ m and the anchoring of the collagen on the nonwoven is no longer sufficiently stable with respect to the mechanical forces applied during handling and application of the sheet material . This can lead to an undesirable detachment of the collagen particles from the nonwoven fabric.
  • Particularly reliable hemostasis can be achieved with a particle size between 100 ⁇ m and 150 ⁇ m.
  • the flat material has 0.4 to 80% by weight, preferably 0.5 to 25% by weight, of collagen particles. It should be noted that the improved haemostatic properties of the sheet material mediated by the collagen are already achieved with approximately 1% by weight of collagen. In this respect, the planar material can have in particular 0.4 to 2% by weight of collagen particles.
  • the collagen particles are arranged at least in sections on the surface of the nonwoven. Due to the size of the collagen particles alone, the surface material is Area of collagen particles more hydrophilic than in the other surface areas without collagen particles. With this structure of the flat material, an immediate bioavailability of the collagen particles and thus a particularly rapid hemostatic effect of the cover membrane can be achieved when applied to a wound. This is also an advantage with regard to a possible intraperitoneal use of the surface material, for example for adhesion prophylaxis. According to a further embodiment of the planar material, the collagen particles are all arranged on the surface of the nonwoven.
  • the collagen particles can in particular be made from native collagen of type I and/or type III, in particular bovine, porcine or murine collagen. Such collagen is available on the market in sufficient quantities and in high purity.
  • the polymer filaments can in particular be an absorbable polymer, in particular a polymer made from at least 2 different monomers (copolymer, terpolymer, etc.) based on the monomers lactide, glycolide, trimethylencarbonate, E-caprolactone and/or 1,4-dioxane-2-one or polyhydroxybutyrate (PHB) or mixtures of these polymers.
  • the flat material can develop an anti-infective and pain-reducing effect analogously to the flat material mentioned at the outset, with the complete hydrolytic and enzymatic degradability being fully retained in vivo.
  • the planar material can be a nonwoven fabric with polymer filaments made from 20% by weight to 99.5% by weight of copolymer and/or polyhydroxybutyrate and 0.4% by weight to 80% by weight of collagen particles with a particle size >80 ⁇ m , preferably 0.5% by weight to 25% by weight collagen particles, very particularly preferably from 0.5 to 2% by weight collagen particles.
  • Such a flat material has a wide range of clinical uses with good haemostatic properties.
  • the polymer filaments of the nonwoven can in particular be a terpolymer of 65 to 87% by weight lactide, 5 to 20% by weight trimethylene carbonate and 5 to 20% by weight s-caprolactone.
  • the monomers lactide, trimethylene carbonate and ⁇ -caprolactone can be present in the terpolymer in particular in the range from 87/8/5 to 70/20/10% by weight.
  • the planar material preferably has a (nominal) thickness d of from 50 to 3000 ⁇ m, preferably from 80 to 500 ⁇ m or from 800 to 2500 ⁇ m.
  • a lower (nominal) thickness of the surface material even allows covering of wound surfaces with an extremely complex geometry.
  • the water-binding capacity of the non-woven fabric which is limited as a result, can be compensated for by a correspondingly larger proportion by weight of collagen particles, if required. Larger nominal thicknesses of the flat material, on the other hand, enable a particularly high water-binding capacity and predestine the flat material for use on heavily bleeding or weeping wounds.
  • the non-woven fabric can be produced in different ways depending on the intended area of use of the sheet material.
  • the nonwoven may be meltblown, i. H. the polymer filaments of the non-woven fabric are produced using the so-called melt-blow process. This allows filament thicknesses of less than 15 ⁇ m to be achieved.
  • the polymer filaments according to the invention can also be produced by means of electrospinning, which is known per se, or centrifugal spinning. In the last two cases, nano-polymer filaments with a filament thickness of a few nanometers can be produced.
  • other known web-forming processes for the production of microfiber or nanofiber webs, such as spun-fiber webs can also be used.
  • the fleece is preferably only doped with the collagen particles after it has been produced, since these cannot cope with the mechanical loads when the polymer filaments are produced.
  • this can be done by sprinkling the (preferably dried) collagen particles and subsequent pressing or calendering of the nonwoven fabric sprinkled with the collagen particles or by means of a wet coating process with subsequent drying of the nonwoven fabric coated with the collagen particles.
  • the collagen particles applied to the non-woven fabric are interwoven with the non-woven fabric Heat input pressed. In this way, the collagen particles can be anchored to the non-woven fabric in a particularly reliable and simple manner.
  • the collagen particles are suspended in an aqueous solution.
  • the suspension of the fibrillar collagen particles has to be carried out very carefully in order not to further damage the collagen particles directly mechanically or through shearing forces, in particular to further comminute them. It is important to preserve the integrity and the desired function of the collagen. It is therefore important to ensure that the size and structure of the collagen particles are suspended. According to the invention, this can be achieved in particular in that the collagen particles are dispersed or suspended in a solvent, in particular in the aqueous solution, by stirring for a maximum of two minutes, preferably for a maximum of one minute.
  • the aqueous solution according to the invention can be enriched with a sugar or even an n-hexane solution can be used to protect the collagen.
  • FIG. 1 shows a planar material according to the invention for medical treatment of wound surfaces with a non-woven fabric made from resorbable polymer filaments and with collagen particles which have a particle size I>80 ⁇ m, in a schematic side view;
  • FIG. 2 shows a microscopically enlarged detail of a planar material with a nonwoven fabric and with collagen particles, magnified 250 times;
  • FIG. 3 shows a microscopically enlarged detail of the planar material according to FIG. 2, magnified 500 times; and 4 shows a microscopically enlarged detail of a flat material in which the nonwoven fabric has been calendered after the collagen particles have been sprinkled on.
  • the planar material 10 comprises a nonwoven fabric 12 made of resorbable polymer filaments 14.
  • the nonwoven fabric 12 has a nominal thickness d, which, depending on the mechanical application requirements placed on the planar material 10, is from 50 to 3,000 ⁇ m, preferably from 80 to 500 ⁇ m or from 1,000 to 2,500 pm, can be.
  • the nonwoven 12 can be produced by the so-called meltblow method or by means of electrospinning or centrifugal spinning or other known nonwoven formation methods for the production of microfibers or nanofibers.
  • the absorbable polymer filaments 14 consist of an absorbable polymer made from at least 2 monomers, in particular a co- or terpolymer based on the monomers lactide, trimethylene carbonate, E-caprolactone and/or 1,4-dioxan-2-one, polyhydroxybutyrate (PHB) or mixtures these polymers.
  • the polymer filaments 14 are therefore biocompatible and can be hydrolytically degraded in vivo or by endogenous enzymes and completely resorbed.
  • the flat material also has collagen particles 16 with a particle size I of more than 80 ⁇ m.
  • the collagen particles 16 are held on or in the nonwoven fabric 12 and are used for improved hemostasis or faster absorption of blood and wound fluid.
  • the collagen particles 16 all consist of comminuted native collagen, for example type I and/or type III collagen, and can in particular be of bovine, murine or porcine origin.
  • the collagen particles 14 can have a particle size I of between 80 ⁇ m and 500 ⁇ m, preferably between 100 ⁇ m and 500 ⁇ m, particularly preferably between 100 ⁇ m and 250 ⁇ m.
  • the fibrillar collagen particles 16 of the planar material thus quickly withdraw water from a bleeding wound and thus accelerate the staunching of blood.
  • the combination of the collagen particles 16 and the synthetic resorbable polymer non-woven fabric 12 e.g.
  • poly-lactide-caprolactone-trimentethylene carbonate combines the positive properties of both materials.
  • the resorbable polymer filaments 14 of the planar material 10 are in direct contact with the wound (eg burn wound) and can improve wound healing through the enzymatic release of lactic acid and develop a pain-relieving and anti-infective effect. In practice it has been shown that even small mass fractions of the collagen particles 14 promote the aforementioned effects.
  • the planar material 10 can comprise between 0.4 and 80% by weight of collagen particles 14, preferably between 0.5 and 25% by weight, very particularly preferably between 0.4 and 2% by weight, of collagen particles 14.
  • the nonwoven fabric 12 containing collagen is more hydrophilic in comparison to an absorbable nonwoven fabric 12 of the same construction without collagen particles 16 and therefore has less of a tendency to stick to itself.
  • the flat material 10 is thus easier to handle in clinical practice.
  • the non-woven fabric 12 can be doped with the collagen particles 16 in different ways. So can the non-woven fabric
  • native collagen of bovine, porcine or murine origin is comminuted to form collagen particles 14 with a particle size greater than 80 ⁇ m, preferably greater than 100 ⁇ m.
  • a non-woven fabric is produced from polymer filaments by means of the melt-blow process, electrospinning or centrifugal spinning of a statistical terpolymer of D,L-lactide-trimethylene carbonate-caprolactone.
  • the collagen particles are scattered onto the nonwoven 12 and then at 40 ° C, 10 bar and 40 sec. pressed with the nonwoven 12.
  • a planar material 10 is obtained in which the nonwoven fabric 12 has collagen particles 16 with a grain or particle size I of >80 ⁇ m on its surface, as is shown in FIGS. 2 and 3 is shown.
  • an aqueous suspension of collagen particles 16 with a particle size >80 ⁇ m is provided. Care must be taken here that the collagen particles 16 retain their size and functionality.
  • extremely gentle stirring in particular for a limited time, is indicated in order not to further break up or destroy the collagen particles 16 directly or through shearing.
  • a dispersing device from the Ultra Turrax® series from IKA®-Werke GmbH & CO. KG, Germany.
  • the non-woven fabric 12 is then dipped into the aqueous collagen suspension or the aqueous collagen suspension is sprayed, rolled or brushed onto the non-woven fabric 12 . Finally, the nonwoven fabric 12 doped with the collagen particles 16 is dried, preferably in a vacuum and at room temperature. In this way, a planar material 10 shown in FIG. 4 is obtained from an absorbable non-woven fabric 12 with collagen particles of >80 ⁇ m.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un matériau bidimensionnel pour le traitement médical d'une zone de plaie, comprenant un non-tissé (12) consistant en des filaments polymères résorbables (14), et des particules de collagène (16) qui ont une taille de particule I > 80 µm et sont disposées sur et/ou dans le non-tissé.
EP21835199.7A 2020-12-03 2021-12-03 Matériau bidimensionnel pour le traitement médical d'une zone de plaie Pending EP4232103A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020215320.5A DE102020215320A1 (de) 2020-12-03 2020-12-03 Flächenmaterial zur medizinischen Wundflächenbehandlung
PCT/EP2021/084219 WO2022117844A1 (fr) 2020-12-03 2021-12-03 Matériau bidimensionnel pour le traitement médical d'une zone de plaie

Publications (1)

Publication Number Publication Date
EP4232103A1 true EP4232103A1 (fr) 2023-08-30

Family

ID=79170696

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21835199.7A Pending EP4232103A1 (fr) 2020-12-03 2021-12-03 Matériau bidimensionnel pour le traitement médical d'une zone de plaie

Country Status (7)

Country Link
EP (1) EP4232103A1 (fr)
JP (1) JP7731426B2 (fr)
KR (1) KR20230116853A (fr)
DE (1) DE102020215320A1 (fr)
MX (1) MX2023006609A (fr)
PE (1) PE20231509A1 (fr)
WO (1) WO2022117844A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3429038A1 (de) * 1984-08-07 1986-02-20 B. Braun Melsungen Ag, 3508 Melsungen Wirkstoff-depot
DE10041684A1 (de) 2000-08-24 2002-03-07 Inst Textil & Faserforschung Beschichtungsmaterial zur medizinischen Behandlung aus resorbierbarem synthetischem Material, Verfahren zu seiner Herstellung und Verwendung in der Medizin
DE102005042707A1 (de) * 2005-09-01 2007-03-08 Polymedics Innovations Gmbh Formkörper zur medizinischen Behandlung von Wunden
DE102007024220A1 (de) 2007-05-15 2008-11-20 Aesculap Ag Blutstillendes Vlies
GB2461019B (en) 2008-04-25 2013-06-05 Medtrade Products Ltd Haemostatic material
CA2910748C (fr) * 2013-05-15 2021-03-30 Euroresearch S.R.L. Poudre de collagene, composition et utilisation associees
US10765774B2 (en) 2013-07-09 2020-09-08 Ethicon, Inc. Hemostatic pad assembly kit and method

Also Published As

Publication number Publication date
DE102020215320A1 (de) 2022-06-23
MX2023006609A (es) 2023-06-19
JP2023551571A (ja) 2023-12-08
US20230302190A1 (en) 2023-09-28
WO2022117844A1 (fr) 2022-06-09
JP7731426B2 (ja) 2025-08-29
PE20231509A1 (es) 2023-09-26
KR20230116853A (ko) 2023-08-04

Similar Documents

Publication Publication Date Title
DE60126142T2 (de) Bioabsorbierbare wundauflage
EP3104900B1 (fr) Produit medical et procede de fabrication correspondant
EP2126166B1 (fr) Tissu non tissé à fibres disposées de manière aléatoire
DE60310815T2 (de) Hämostatischer Wundverband und Verfahren zu deren Herstellung
DE2515970A1 (de) Verdichteter filz
DE69412319T2 (de) Hydrokolloidverband
EP2627813B1 (fr) Fibres hydrogélifiantes ainsi que structure fibreuse hydrogélifiante
EP2042199B1 (fr) Pansements biorésorbables
WO2019121376A1 (fr) Pansement régulant le ph
DE10318801A1 (de) Flächiges Implantat und seine Verwendung in der Chirurgie
DE2359949A1 (de) Nassverlegtes, ungewebtes, blutstillendes schichtgebilde aus faserigem kollagen fuer heil- und wundbehandlung
EP2320844A1 (fr) Article pour le soin des plaies contenant une proportion de fibres naturelles modifiées ou de fibres synthétiques
WO2009019227A2 (fr) Article pour le soin des plaies, présentant des polymères super-absorbants sous forme de fibres et/ou de fils
EP2812037B1 (fr) Non-tissé biodégradable à usage médical
EP2011523B1 (fr) Etoffe hémostatique
WO2010031862A2 (fr) Utilisation de fibres lyocell et articles contenant des fibres lyocell
EP4232103A1 (fr) Matériau bidimensionnel pour le traitement médical d'une zone de plaie
DE102011115818A1 (de) Vliesstoff mit hohem Quellvermögen
US12616772B2 (en) Two-dimensional material for medical wound area treatment
DE102013203997A1 (de) Medizinisches Produkt
DE102013019888A1 (de) Hydrogelierende Fasern sowie Fasergebilde
DE20122661U1 (de) Biologisch absorbierbarer Wundverband
EP4232102A2 (fr) Membrane de recouvrement résorbable pour traitement médical de zone de plaie
EP4452343B1 (fr) Pansements, gel pour les plaies et produit cosmétique
WO2007085391A1 (fr) Structure et utilisation de cette structure en tant que pansement de contact direct avec la plaie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241121